功能遗传筛查鉴定磷酸肌醇3-激酶通路为FGFR突变尿路上皮癌对成纤维细胞生长因子受体抑制剂耐药的决定因素
在FGFR3-TACC3易位的尿路上皮癌细胞系RT112中,用靶向人激酶组的短发夹RNA文库对FGFR抑制剂AZD4547进行合成致死筛查,发现PI3K通路多个成员,抑制PIK3CA与FGFR抑制剂协同;PI3K抑制剂BKM120在多种携带FGFR突变的尿路上皮癌和肺癌细胞系中与FGFR抑制协同。
要点
- 在RT112细胞中筛查发现PI3K通路成员与FGFR抑制剂AZD4547协同。
- 抑制PIK3CA与FGFR抑制剂协同,BKM120在多种FGFR突变癌细胞系中协同。
- FGFR抑制导致EGFR或ERBB3再激活,上调PI3K-AKT通路活性,为协同的分子机制。
核心结论
- FGFR抑制激活的反馈通路汇聚于PI3K通路,为在FGFR基因遗传激活的癌症中联合检测FGFR抑制剂与PI3K抑制剂提供依据。
研究设计与样本
- 在尿路上皮癌细胞系RT112(FGFR3-TACC3易位)中,用靶向人激酶组的短发夹RNA文库对FGFR抑制剂AZD4547进行合成致死筛查。
- 在多种携带FGFR突变的尿路上皮癌和肺癌细胞系中检测PI3K抑制剂BKM120与FGFR抑制的联合效应。
主要发现
- 筛查鉴定出PI3K通路多个成员,抑制PIK3CA与FGFR抑制剂协同。
- PI3K抑制剂BKM120在多种携带FGFR突变的尿路上皮癌和肺癌细胞系中与FGFR抑制协同。
- FGFR抑制导致EGFR或ERBB3再激活,引起PI3K-AKT通路活性升高,为协同的分子机制。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Activating mutations and translocations of the FGFR3 gene are commonly seen in urothelial cell carcinoma (UCC) of the bladder and urinary tract. Several fibroblast growth factor receptor (FGFR) inhibitors are currently in clinical development and response rates appear promising for advanced UCC. A common problem with targeted therapeutics is intrinsic or acquired resistance of the cancer cells. To find potential drug targets that can act synergistically with FGFR inhibition, we performed a synthetic lethality screen for the FGFR inhibitor AZD4547 using a short hairpin RNA library targeting the human kinome in the UCC cell line RT112 (FGFR3-TACC3 translocation). We identified multiple members of the phosphoinositide 3-kinase (PI3K) pathway and found that inhibition of PIK3CA acts synergistically with FGFR inhibitors. The PI3K inhibitor BKM120 acted synergistically with inhibition of FGFR in multiple UCC and lung cancer cell lines having FGFR mutations. Consistently, we observed an elevated PI3K-protein kinase B pathway activity resulting from epidermal growth factor receptor or Erb-B2 receptor tyrosine kinase 3 reactivation caused by FGFR inhibition as the underlying molecular mechanism of the synergy. Our data show that feedback pathways activated by FGFR inhibition converge on the PI3K pathway. These findings provide a strong rationale to test FGFR inhibitors in combination with PI3K inhibitors in cancers harboring genetic activation of FGFR genes.
引用
- Wang L, Šuštić T, Leite de Oliveira R, et al. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. Eur Urol. 2017. PMID: 28108151. doi:10.1016/j.eururo.2017.01.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。